KalVista Pharmaceuticals Inc. (KALV) Financial Ratios & Valuation Metrics Analysis - P/E, ROE, Debt Ratios & Profitability - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    KalVista Pharmaceuticals ...

    NASDAQ: KALV · Real-Time Price · USD
    15.82
    0.62 (4.08%)
    At close: Sep 05, 2025, 3:59 PM
    15.82
    0.00%
    After-hours: Sep 05, 2025, 07:05 PM EDT

    KalVista Pharmaceuticals Ratios and Metrics

    Financials in USD. Fiscal year is May - April.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Apr 30, 2025 Apr 30, 2024 Apr 30, 2023 Apr 30, 2022 Apr 30, 2021
    PE Ratio
    		 -3.73 -3.3 -3.31 -4.55 -10.72
    PEG Ratio
    		 -0.51 -0.12 0.77 -0.23 -0.25
    PS Ratio
    		 n/a n/a n/a n/a 37.57
    PB Ratio
    		 7.17 2.02 1.54 1.68 1.85
    P/FCF Ratio
    		 -4.47 -4.66 -3.24 -3.94 -15.76
    P/OCF Ratio
    		 -4.47 -4.68 -3.29 -3.99 -15.8
    OCF/S Ratio
    		 n/a n/a n/a n/a -2.38
    Debt / Equity Ratio
    		 0.07 0.04 0.05 0.04 0.02
    Quick Ratio
    		 5.35 9.90 11.46 16.49 27.04
    Current Ratio
    		 5.35 9.90 11.46 16.73 27.04
    Asset Turnover
    		 n/a n/a n/a n/a 0.05
    Interest Coverage
    		 -32.5 n/a n/a -88.64 n/a
    Return on Equity
    		 -1.92 -0.61 -0.46 -0.37 -0.17
    Return on Assets
    		 -0.73 -0.54 -0.41 -0.34 -0.16
    Return on Invested Capital
    		 -0.92 -0.62 -0.53 -0.42 -0.21
    Dividend Yield
    		 n/a n/a n/a n/a n/a
    Payout Ratio
    		 n/a n/a n/a n/a n/a
    Gross Profit Margin
    		 n/a n/a n/a n/a 0.95
    Net Profit Margin
    		 n/a n/a n/a n/a -3.51
    Pretax Profit Margin
    		 n/a n/a n/a n/a -3.64
    Operating Profit Margin
    		 n/a n/a n/a n/a -4.56
    FCF Margin
    		 n/a n/a n/a n/a -2.38
    EBITDA Margin
    		 n/a n/a n/a n/a -3.59

    Add to Watchlist